Promising COVID-19 Vaccine Results From Pfizer & Moderna
Within the race of finding a safe, effective vaccine for COVID-19, promising news was released lately from two big pharmaceutical companies, Pfizer & Moderna, each about their proposed vaccine. Pfizer, and their German Biotech partner BionTech, announced the first interim efficacy analysis of their vaccine candidate . The vaccine was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection . Pfizer’s study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed . The analysis evaluated 94 confirmed cases of COVID-19 in trial participants . Based on the current projections, they are expecting to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021 . However, challenges related to the vaccine ultra-low temperature formulation and attendant storage that reaches (-70) degree Celsius, could affect the availability or commercial potential of the vaccine, as announced by Pfizer . On the other hand, the U.S. Biotech company, Moderna, announced that the clinical trial in its vaccine candidate met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5% . The study, known as the COVE study, enrolled more than 30,000 participants in the U.S . The first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the vaccine group, resulting in a point estimate of vaccine efficacy of 94.5% . Moderna also pointed to the storage advantage of their candidate vaccine that can remain stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days, up from previous estimate of 7 days . By the end of 2020, Moderna expects to have approximately 20 million doses of the vaccine ready to ship in the U.S., while aiming to manufacture 500 million to 1 billion doses globally in 2021 .
- Pfizer And Biontech Announce Vaccine Candidate Against COVID-19 Achieved Success In First Interim Analysis From Phase 3 Study. Pfizer, 2020, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against. Accessed 16 Nov 2020.
- Moderna’S COVID-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint In The First Interim Analysis Of The Phase 3 COVE Study. Moderna, Inc. 2020, https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy. Accessed 16 Nov 2020.
- Moderna Announces Longer Shelf Life For Its COVID-19 Vaccine Candidate At Refrigerated Temperatures. Moderna Inc., 2020, https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine.